Antioxidants may shield kidneys from colistin damage in ICU patients
NCT ID NCT06650384
First seen Feb 28, 2026 · Last updated Jun 21, 2026 · Updated 17 times
Summary
This completed trial tested whether two antioxidants, N-acetylcysteine and alpha-lipoic acid, could prevent kidney damage caused by the antibiotic colistin in 180 critically ill patients. Participants received either colistin alone or colistin plus one of the antioxidants. The study tracked kidney function daily to see if the antioxidants reduced the risk of acute kidney injury.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEPHROTOXICITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Critical Care Medicine Department,Cairo University Hospitals
Cairo, Egypt
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
N-acetylcysteine and alpha-lipoic acid
What this could lead to
If successful, this could point toward a simple way to protect kidneys in critically ill patients who need colistin, reducing the risk of kidney failure.
What could go wrong
This is a completed Phase 2/3 trial, but results are not yet widely confirmed. The benefit may be small or not apply to all patients, and antioxidants can have side effects.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.